CD44 as a potential diagnostic tumor marker

Saudi Medical Journal

Volumn 36, Issue 3, 2015, Pages 273-279

  Basakran, Nawwaf S ^a  

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CD44V ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR; FIBROBLAST GROWTH FACTOR 2; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; HERMES ANTIGEN; HYALURONIC ACID; INTERLEUKIN 1BETA; INTERLEUKIN 8; PROTEIN TYROSINE KINASE; T LYMPHOCYTE RECEPTOR; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; CD33 ANTIGEN;

BREAST CANCER; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; COLON CANCER; DENDRITIC CELL; DOWN REGULATION; GENE; HUMAN; INTESTINE CANCER; LEUKEMIA; LIVER CANCER CELL LINE; PREVALENCE; REVIEW; NEOPLASMS;

BIOMARKERS, TUMOR; HUMANS; NEOPLASMS; SIALIC ACID BINDING IG-LIKE LECTIN 3;

EID: 84924415176     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: 10.15537/smj.2015.3.9622     Document Type: Review

References (28)

1. Gee K, Kryworuchko M, Kumar A. Recent advances in the regulation of CD44 expression and its role in inflammation and autoimmune diseases. Arch Immunol Ther Exp (Warsz) 2004; 52: 13-26.
2. Olsson E, Honeth G, Bendahl PO, Saal LH, Gruvberger-Saal S, Ringnér M, et al. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer 2011; 11: 418.
3. Akisik E, Bavbek S, Dalay N. CD44 variant exons in leukemia and lymphoma. Pathol Oncol Res 2002; 8: 36-40.
4. Hegde VL, Singh NP, Nagarkatti PS, Nagarkatti M. CD44 mobilization in allogeneic dendritic cell-T cell immunological synapse plays a key role in T cell activation. J Leukoc Biol 2008; 84: 134-142.
5. Termeer C, Averbeck M, Hara H, Eibel H, Herrlich P, Sleeman J, et al. Targeting dendritic cells with CD44 monoclonal antibodies selectively inhibits the proliferation of naive CD4+ T-helper cells by induction of FAS-independent T-cell apoptosis. Immunology 2003; 109: 32-40.
6. Guo W, Frenette PS. Alternative CD44 splicing in intestinal stem cells and tumorigenesis. Oncogene 2014; 33: 537-538.
7. Williams K, Motiani K, Giridhar PV, Kasper S. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp Biol Med (Maywood) 2013; 238: 324-338.
8. Bennett KL, Jackson DG, Simon JC, Tanczos E, Peach R, Modrell B, et al. CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol 1995; 128: 687-698.
9. Delon I, Brown NH. Integrins and the actin cytoskeleton. Curr Opin Cell Biol 2007; 19: 43-50.
10. Okuda H, Kobayashi A, Xia B, Watabe M, Pai SK, Hirota S, et al. Hyaluronan synthase HAS2 promotes tumor progression in bone by stimulating the interaction of breast cancer stem-like cells with macrophages and stromal cells. Cancer Res 2012; 72: 537-547.
11. Afify A, Purnell P, Nguyen L. Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion. Exp Mol Pathol 2009; 86: 95-100.
12. Fillmore C, Kuperwasser C. Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man? Breast Cancer Res 2007; 9: 303.
13. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100: 672-679.
14. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinase signaling as a target for cancer intervention strategies. Endocr Relat Cancer 2001; 8: 161-173.
15. Bourguignon LY, Zhu H, Chu A, Iida N, Zhang L, Hung MC. Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation. J Biol Chem 1997; 272: 27913-27918.
16. Meran S, Luo DD, Simpson R, Martin J, Wells A, Steadman R, et al. Hyaluronan facilitates transforming growth factor-ß1- dependent proliferation via CD44 and epidermal growth factor receptor interaction. J Biol Chem 2011; 286: 17618-17630.
17. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 2008; 14: 6364-6370.
18. Bao W, Fu HJ, Xie QS, Wang L, Zhang R, Guo ZY, et al. HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. Gastroenterology 2011; 141: 2076-2087. CD44 as a potential diagnostic tumor marker Basakran
19. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011; 19: 387-400.
20. Ghaffari S, Dougherty GJ, Lansdorp PM, Eaves AC, Eaves CJ. Differentiation-associated changes in CD44 isoform expression during normal hematopoiesis and their alteration in chronic myeloid leukemia. Blood 1995; 86: 2976-2985.
21. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006; 12: 1167-1174.
22. Sconocchia G, Campagnano L, Adorno D, Iacona A, Cococcetta NY, Boffo V, et al. CD44 ligation on peripheral blood polymorphonuclear cells induces interleukin-6 production. Blood 2001; 97: 3621-3627.
23. Xie Z, Choong PF, Poon LF, Zhou J, Khng J, Jasinghe VJ, et al. Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion. Cancer Chemother Pharmacol 2008; 62: 949-957.
24. Zhang S, Wu CC, Fecteau JF, Cui B, Chen L, Zhang L, et al. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc Natl Acad Sci U S A 2013; 110: 6127-6132.
25. Gadhoum Z, Leibovitch MP, Qi J, Dumenil D, Durand L, Leibovitch S, et al. CD44: a new means to inhibit acute myeloid leukemia cell proliferation via p27Kip1. Blood 2004; 103: 1059-1068.
26. Van Etten RA. New insights into the normal and leukemic stem cell niche: a timely review. Cytometry B Clin Cytom 2013; 84: 5-6.
27. Alam TN, O’Hare MJ, Laczkó I, Freeman A, Al-Beidh F, Masters JR, et al. Differential expression of CD44 during human prostate epithelial cell differentiation. J Histochem Cytochem 2004; 52: 1083-1090.
28. Zöller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011; 11: 254-267.